

NCT ID	Study Title	Status	Conditions ¹	Phase	(Expected) Completion	Study Locations
NCT03206073	A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer	Recruiting	Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma	Phase 1/2	December 31, 2020	United States
NCT03294486	Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients	Recruiting	Glioblastoma, Brain Cancer	Phase 1/2	May 1, 2019	France
NCT03004183	SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC	Recruiting	Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer	Phase 2	May 1, 2022	United States
NCT03954067	A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors	Not yet recruiting	Metastatic Cancer, Solid Tumors, Advanced Cancer	Phase 1	March 1, 2022	
NCT02705196	LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer	Recruiting	Pancreatic Cancer	Phase 1/2	November 1, 2019	United States
NCT00794131	Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors	Completed	Advanced Cancers (Solid Tumors)	Phase 1	November 1, 2015	United Kingdom
NCT02365818	Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure	Completed	Bladder Cancer	Phase 2	August 1, 2018	United States

NCT004 08590	Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer	Completed	Ovarian Cancer, Primary Peritoneal Cavity Cancer	Phase 1	August 1, 2012	United States
NCT038 66525	OH2 Oncolytic Viral Therapy in Solid Tumors	Recruiting	Solid Tumor, Gastrointestinal Cancer	Phase 1	December 31, 2020	China
NCT031 90824	Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma	Active, not recruiting	Melanoma Stage III, Melanoma Stage IV	Phase 2	June 24, 2021	United States
NCT039 16510	Chemoradiation With Enadenotucirev as a Radiosensitizer in Locally Advanced Rectal Cancer	Not yet recruiting	Locally Advanced Rectal Cancer	Phase 1	March 1, 2022	United Kingdom
NCT037 14334	DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma	Recruiting	Glioblastoma, Glioblastoma, Adult	Phase 1	April 16, 2022	Spain
NCT024 28036	A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions	Completed	Solid Tumor	Phase 1	October 1, 2016	Japan
NCT032 52808	Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Japanese Patients With Unresectable Pancreatic Cancer.	Active, not recruiting	Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV	Phase 1	May 31, 2020	Japan
NCT031 53085	A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma	Completed	Melanoma Stage III, Melanoma Stage IV	Phase 2	June 30, 2018	Japan
NCT027 14374	Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to	Active, not recruiting	Solid Organ Cancers	Phase 1	March 1, 2019	United States

	Patients With Solid Organ Cancers Undergoing Surgery					
NCT02272855	A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma	Completed	Malignant Melanoma	Phase 2	October 1, 2016	United States
NCT03605719	Dexamethasone, Carfilzomib, & Nivolumab With Reovirus for Relapsed/Refractory Multiple Myeloma	Recruiting	Recurrent Plasma Cell Myeloma	Phase 1	October 31, 2021	United States
NCT00028158	Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer	Completed	Glioma, Astrocytoma, Glioblastoma	Phase 1/2		
NCT03740256	Binary Oncolytic Adenovirus in Combination With HER2-Specific CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)	Not yet recruiting	Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland	Phase 1	January 1, 2023	
NCT03152318	A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2	Recruiting	Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma	Phase 1	July 1, 2021	United States
NCT01721018	Intrpleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.	Completed	Malignant Pleural Mesothelioma	Phase 1/2	November 14, 2016	United Kingdom
NCT00528684	Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas	Completed	Malignant Glioma	Phase 1	April 1, 2010	United States
NCT02977156	Immunization Strategy With Intratumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.	Recruiting	Metastatic Tumor, Advanced Tumor	Phase 1	December 1, 2019	France

NCT020 53220	Mechanism of Action Trial of ColoAd1	Completed	Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer	Phase 1	April 1, 2015	Spain
NCT021 97169	DNX-2401 With Interferon Gamma (IFN- γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors	Completed	Glioblastoma or Gliosarcoma	Phase 1	March 15, 2018	United States
NCT020 28442	Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients	Completed	Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer	Phase 1/2	April 29, 2016	Spain
NCT020 28117	Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients	Recruiting	Recurrent Platinum Resistant Ovarian Cancer	Phase 1	August 1, 2019	United Kingdom
NCT027 79855	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer	Recruiting	Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma	Phase 1/2	August 31, 2021	United States
NCT009 31931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	Completed	Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma	Phase 1	March 19, 2018	United States
NCT037 47744	Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)	Recruiting	Melanoma	Phase 1	October 1, 2019	Belgium
NCT034 08587	CAVATAK [®] and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)	Active, not recruiting	Uveal Melanoma, Liver Metastases	Phase 1	January 14, 2020	United States

NCT012 27551	A Study of Intratumoral CAVATAKâ„¢ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM)	Completed	Malignant Melanoma	Phase 2	July 15, 2015	United States
NCT004 29312	A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma	Completed	Melanoma	Phase 1/2	February 1, 2008	United States
NCT015 98129	ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers	Completed	Malignant Solid Tumour	Phase 1	October 1, 2013	Finland
NCT004 38009	A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)	Completed	Stage IV Melanoma	Phase 1	August 28, 2009	Australia
NCT013 01430	Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.	Completed	Glioblastoma Multiforme	Phase 1/2	May 1, 2015	Germany
NCT027 98406	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects	Active, not recruiting	Brain Cancer, Brain Neoplasm, Glioma	Phase 2	December 1, 2020	United States
NCT038 89275	A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors	Not yet recruiting	Advanced Solid Tumors	Phase 1	March 27, 2025	United Kingdom
NCT036 18953	This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers	Active, not recruiting	HPV-Associated Cancers	Phase 1	June 1, 2020	International
NCT005 03295	Safety and Efficacy Study of REOLYSINÂ® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung	Completed	Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma	Phase 2	February 1, 2011	United States

NCT020 62827	Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma	Recruiting	Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma	Phase 1	September 1, 2019	United States
NCT002 89016	A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma	Completed	Melanoma	Phase 2	December 1, 2008	International
NCT014 43260	A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis	Completed	Peritoneal Carcinomatosis	Phase 1/2	September 1, 2014	Germany
NCT037 73744	MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma	Not yet recruiting	Metastatic Melanoma, Squamous Cell Skin Carcinoma	Phase 1	October 30, 2020	
NCT036 57576	Trial of C134 in Patients With Recurrent GBM	Not yet recruiting	Glioblastoma Multiforme of Brain, Anaplastic Astrocytoma of Brain, Gliosarcoma of Brain	Phase 1	May 1, 2022	United States
NCT020 45602	Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors	Active, not recruiting	Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma	Phase 1	May 1, 2019	Spain

NCT027 59588	GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer	Recruiting	Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer	Phase 1/2	December 1, 2019	United States
NCT025 62755	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone	Recruiting	Hepatocellular Carcinoma (HCC)	Phase 3	December 1, 2020	United States
NCT020 45589	A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer	Completed	Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma	Phase 1	October 1, 2016	Spain
NCT015 84284	Safety Study of Attenuated Vaccinia Virus (GL-ONC1) With Combination Therapy in Head & Neck Cancer	Completed	Cancer of Head and Neck	Phase 1	June 1, 2015	United States
NCT006 25456	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors	Completed	Melanoma, Lung Cancer, Renal Cell Carcinoma	Phase 1	April 1, 2010	International
NCT003 14925	Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features	Unknown status	Carcinoid, Neuroendocrine	Phase 1	December 1, 2008	International
NCT028 79760	Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients	Active, not recruiting	Non-Small Cell Lung Cancer	Phase 1/2	January 1, 2020	Canada
NCT039 11388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Not yet recruiting	Brain Neoplasms, Glioblastoma Multiforme,	Phase 1	July 1, 2022	United States

			Glioblastoma of Cerebellum			
NCT006 29759	A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma	Completed	Neoplasms, Liver	Phase 1	July 1, 2007	Korea, Republic of
NCT011 69584	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	Completed	Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor	Phase 1	March 1, 2012	United States
NCT013 87555	A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib	Completed	Hepatocellular Carcinoma, Liver Cancer, HCC	Phase 2	December 1, 2011	International
NCT005 54372	A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma	Completed	Carcinoma, Hepatocellular	Phase 2	December 1, 2011	International
NCT013 94939	Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma	Completed	Colorectal Carcinoma, CRC	Phase 1/2	June 1, 2015	International
NCT026 20423	Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma	Completed	Pancreatic Adenocarcinoma	Phase 1	March 1, 2018	United States
NCT024 57845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	Recruiting	Malignant Supratentorial Neoplasms, Malignant Glioma, Glioblastoma	Phase 1	April 1, 2020	United States

NCT00861627	Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation	Completed	Carcinoma, Non-small Cell Lung	Phase 2	September 1, 2015	United States
NCT01274624	Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer	Completed	KRAS Mutant Metastatic Colorectal Cancer	Phase 1	February 1, 2018	United States
NCT02192775	UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus	Recruiting	Multiple Myeloma	Phase 2	August 1, 2019	United States
NCT02288897	PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma	Active, not recruiting	Cutaneous Melanoma	Phase 3	March 1, 2019	International
NCT03852511	First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)	Recruiting	Metastatic Cancer, Epithelial Tumor	Phase 1	June 1, 2021	United States
NCT02364713	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Endometrioid Tumor	Phase 2	February 1, 2025	United States
NCT03225989	Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer	Recruiting	Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma	Phase 1/2	December 31, 2020	Sweden

NCT020 68794	MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer	Recruiting	Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma	Phase 1/2	March 10, 2021	United States
NCT015 03177	Intraleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma	Active, not recruiting	Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma	Phase 1	December 1, 2019	United States
NCT038 96568	Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma	Recruiting	IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma	Phase 1	February 28, 2020	United States
NCT032 59425	Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma	Recruiting	Melanoma	Phase 2	October 1, 2022	United States
NCT019 56734	Virus DNX2401 and Temozolomide in Recurrent Glioblastoma	Completed	Glioblastoma Multiforme, Recurrent Tumor	Phase 1	December 1, 2015	Spain
NCT031 78032	Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas	Recruiting	Brainstem Glioma, Neoadjuvant Therapy	Phase 1	August 30, 2019	Spain
NCT004 50814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	Active, not recruiting	Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma	Phase 1/2	July 10, 2018	United States

NCT030 43391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	Recruiting	Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma	Phase 1	July 1, 2020	United States
NCT030 72134	Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma	Recruiting	Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma	Phase 1	March 30, 2019	United States
NCT011 99263	Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma	Phase 2	September 1, 2019	United States
NCT032 94083	A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma	Recruiting	Renal Cell Carcinoma	Phase 1	November 1, 2019	International
NCT030 03676	A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade	Recruiting	Advanced or Unresectable Melanoma Progressing After PD1 Blockade	Phase 1	June 1, 2020	United States

Supplemental Table 1: List of Oncolytic virus trials on ClinicalTrials.gov as of June 03, 2019. ¹The first three indications listed on ClinicalTrials.gov are included.